Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIXT Lixte Biotechnology Holdings Inc.

Trading 01-16 11:18:38 EST

3.37

-0.04

-1.27%

High3.41	Low3.35	Vol7.44K
Open3.40	D1 Closing3.41	Amplitude1.76%
Mkt Cap29.30M	Tradable Cap26.91M	Total Shares8.70M
T/O25.13K	T/O Rate0.09%	Tradable Shares7.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LIXT","market":"US","secType":"STK","nameCN":"Lixte Biotechnology Holdings Inc.","latestPrice":3.3667,"timestamp":1768580201102,"preClose":3.41,"halted":0,"volume":7437,"delay":0,"floatShares":7992100,"shares":8703100,"eps":-1.211027,"marketStatus":"Trading","change":-0.0433,"latestTime":"01-16 11:18:38 EST","open":3.4027,"high":3.41,"low":3.35,"amount":25130.792840100003,"amplitude":0.017595,"askPrice":3.44,"askSize":205,"bidPrice":3.38,"bidSize":401,"shortable":3,"etf":0,"ttmEps":-1.211027,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768597200000},"marketStatusCode":2,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":3.41,"postHourTrading":{"tag":"盘后","latestPrice":3.41,"preClose":3.41,"latestTime":"19:55 EST","volume":5,"amount":17.11,"timestamp":1768524954390},"volumeRatio":0.393983},"requestUrl":"/m/hq/s/LIXT/wiki","defaultTab":"wiki","newsList":[{"id":"2602915053","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2602915053","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602915053?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:00","pubTimestamp":1767891614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, January 8th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collabo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-expands-ovarian-cancer-trial-with-md-anderson-and-gsk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-expands-ovarian-cancer-trial-with-md-anderson-and-gsk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","BK4139","SQQQ",".IXIC","LIXT","GSK","QID","BK4532","QLD","BK4585","PSQ","BK4588","GSK.UK","LU1829250122.USD","TSYW.SI","BK4196","BK4007","NQmain","USAW.SI","NVIW.SI","USJW.SI","MD","MNQmain"],"gpt_icon":0},{"id":"2600709771","title":"Lixte Biotechnology Announces Unregistered Share Exchange with Orbit Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2600709771","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600709771?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:01","pubTimestamp":1767214883,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has announced the completion of a share exchange agreement with Orbit Capital Inc. Under the terms of the agreement, Orbit Capital exchanged 2,700 shares of Lixte’s Series C Preferred Stock for 700,000 shares of Lixte’s common stock and 200 ordinary shares, representing 20% of the outstanding securities, of Lixte’s wholly-owned subsidiary, Liora Technologies Europe Ltd. The transaction, which resulted in the cancellation of all Series C Preferred Shares, was conducted as an unregistered sale of equity securities under exemptions provided by Section 4 and/or Rule 506 of Regulation D of the Securities Act of 1933.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL4BF2Yd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2593027490","title":"Lixte Biotechnology Holdings Inc - Expands Collaboration With University of Texas Md Anderson Cancer Center & GSK for Lb-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2593027490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593027490?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:12","pubTimestamp":1766495559,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505439.SGD","LU0985481810.HKD","LU1015430645.USD","LU1035777561.USD","IE0034235071.USD","LU0203347892.USD","LIXT","IE00BQJZX424.USD","LU1202635105.USD","BK4139","LU0058720904.USD","LU0306806265.USD","LU0161305163.EUR","LU0545562505.USD","LU0575583348.USD","LU0109981661.USD","LU0211331839.USD","LU0225284248.USD","LU1481600234.SGD","LU1481599808.USD","LU1400636657.SGD","LU1228905037.USD","LU0306807586.USD","LU1302929846.USD","LU1400636574.HKD","LU1645745479.HKD","LU1098665638.USD","LU1400636491.USD","LU0289739699.SGD","LU0321505868.SGD","LU0971552830.HKD","LU0971552673.USD","IE00BWDBJ516.SGD","GSK.UK","LU1046248800.SGD","LU1309081286.SGD","IE00B3T34201.USD","LU1064927863.SGD","LU1228905540.USD","LU1670756490.USD","LU0225771236.USD","LU0203345920.USD","BK5011","LU1487256676.USD"],"gpt_icon":0},{"id":"2593490476","title":"Lixte Biotechnology Expands Ovarian Cancer Trial With MD Anderson and GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2593490476","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593490476?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:01","pubTimestamp":1766494869,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has expanded its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on a clinical trial investigating Lixte’s proprietary compound, LB-100, for the treatment of ovarian clear cell cancer. The trial, which combines LB-100 with GSK's immunotherapy drug Dostarlimab, began in January 2024 and has recently added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The expanded partnership will double trial enrollment to 42 patients, with initial findings from the first 21 patients expected to be presented in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL4RZhr4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","LIXT","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","SG9999014021.USD","NDAQ","SG9999014039.USD","BK4588"],"gpt_icon":0},{"id":"2592904336","title":"Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2592904336","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592904336?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:00","pubTimestamp":1766066400,"startTime":"0","endTime":"0","summary":"BOCA RATON, FLA, Dec.  18, 2025  (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207816/0/en/Lixte-Biotechnology-Holdings-Inc-Announces-4-3-Million-Registered-Direct-Offering-Priced-at-the-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2590546572","title":"Lixte Biotechnology Holdings Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546572?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:52","pubTimestamp":1765482745,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. held its Annual Meeting on December 8, 2025. Shareholders approved the election of Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, and Guy Primus to the board of directors. The appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved an amendment to the 2020 Plan, increasing the number of shares of common stock available for issuance from 2.75 million to 3.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLCR9SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2589035560","title":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589035560","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589035560?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200652,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL8qsf6j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2588221046","title":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588221046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588221046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766845,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL5rGJKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2586551402","title":"Lixte Biotechnology Acquires Liora Technologies for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2586551402","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586551402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:26","pubTimestamp":1764109606,"startTime":"0","endTime":"0","summary":"An update from Lixte Biotechnology Holdings ( ($LIXT) ) is now available. On November 24, 2025, LIXTE Biotechnology Holdings completed the acquisit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-acquires-liora-technologies-for-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-acquires-liora-technologies-for-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2586724874","title":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724874?lang=en_us&edition=fundamental","pubTime":"2025-11-25 23:45","pubTimestamp":1764085504,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL6N3X10WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","KEYS","LU2290526834.HKD","ALUR","CDE","LU1116320737.USD","ZETA","ADI","LU1815336760.USD","ABCB","CDW","APD","VST","ANF","FCX","IRD","PTCT","FLNC","DD","LU1066051498.USD","SYM","ESPR","TITN","UPWK","LU0784383803.USD","SG9999000418.SGD","SRPT","LU0323591593.USD","BBY","IE00BN0W2T93.GBP","ZM","AMAT","BK4541","SCCO","FLY","SPOT","HL","KSS","LIXT","FIBK","ATAT"],"gpt_icon":1},{"id":"2586476925","title":"BUZZ-Lixte rises after buying UK firm to enter proton therapy cancer care","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476925?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:53","pubTimestamp":1764078785,"startTime":"0","endTime":"0","summary":"BUZZ-Lixte rises after buying UK firm to enter proton therapy cancer care** Shares of drug developer Lixte Biotechnology LIXT.O rise 7% to $4.78 premarket** Co says it acquired Liora Technologies Europe, which develops proton therapy systems for cancer treatment** Liora's flagship \"LiGHT System\" aims to deliver high-precision proton therapy at lower cost and fewer sessions - LIXT** LIXT says system installed at UK's STFC Daresbury Lab; plans to create a center of excellence for cancer care** Deal expands co beyond cancer drugs into radiotherapy; complements trials of its cancer therapy LB-100 for ovarian and colon cancer** Proton therapy is a type of radiation treatment for cancer that uses protons instead of X-rays to target tumors** Up to last close, stock up ~120% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2586476409","title":"Lixte Biotechnology acquires Liora’s proton therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476409","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476409?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:45","pubTimestamp":1764078350,"startTime":"0","endTime":"0","summary":"LIXTE Biotechnology (LIXT) announced it has completed the acquisition of Liora Technologies Europe, a UK-based company pioneering electronically co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-acquires-lioras-proton-therapy-platform-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-acquires-lioras-proton-therapy-platform-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2586647543","title":"Lixte Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2586647543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586647543?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA6CMTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139","LIXTW"],"gpt_icon":0},{"id":"2576412776","title":"Lixte Biotechnology Holdings Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2576412776","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576412776?lang=en_us&edition=fundamental","pubTime":"2025-10-17 05:26","pubTimestamp":1760650014,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has announced that it will hold its 2025 Annual Meeting of Stockholders on December 8, 2025. During the meeting, shareholders will be asked to vote on the election of five nominees for director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL6bfF2h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2575745330","title":"Lixte Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate Lb-100, Strategic Oncology Business Development and Acquisition Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2575745330","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575745330?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA3W1QLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIXTW","LIXT"],"gpt_icon":0},{"id":"2567360128","title":"Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2567360128","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567360128?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:41","pubTimestamp":1757972467,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. Announces Leadership Reshuffle with Geordan Pursglove as CEO and Bas van der Baan as Chief Scientific Officer. Lixte Biotechnology Holdings Inc. has announced significant management changes as part of its strategic realignment. Geordan Pursglove has been appointed as Chairman and CEO, while former CEO Bas van der Baan has transitioned to the role of Chief Scientific Officer. These changes are aimed at sharpening the company's focus on scientific development and operational strategy. The company has also reconstituted its Scientific Advisory Committee and relocated its headquarters to Boca Raton, Florida, signaling a renewed commitment to its growth and innovation objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLb0BTjT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2566291308","title":"Lixte Biotechnology Invests $2.6M in Cryptocurrencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2566291308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566291308?lang=en_us&edition=fundamental","pubTime":"2025-09-12 01:47","pubTimestamp":1757612873,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Lixte Biotechnology Holdings ( ($LIXT) ). On September 10, 2025, LIXTE Biotechnology Holdings announced a $2.6 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-invests-2-6m-in-cryptocurrencies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-invests-2-6m-in-cryptocurrencies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2566982087","title":"Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum  for $2.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2566982087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566982087?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:35","pubTimestamp":1757536540,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology (LIXT) announced it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potenti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-purchases-10-5-bitcoin-300-ethereum-for-2-6m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lixte-biotechnology-purchases-10-5-bitcoin-300-ethereum-for-2-6m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["US6M.BOND","QETH","US12M.BOND","US7Y.BOND","ETHV","BK4594","EZET","BK4139","BK4585","US3Y.BOND","US2Y.BOND","BK4588","US5Y.BOND","BK4601","US30Y.BOND","CETH","US10Y.BOND","LIXT","FETH","METHmain","MBTmain"],"gpt_icon":0},{"id":"2566984763","title":"Lixte Biotechnology Holdings Inc - Purchases 10.5 Bitcoin and 300 Ethereum for $2.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2566984763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566984763?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:10","pubTimestamp":1757535046,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX1BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","LIXTW","BK4139"],"gpt_icon":0},{"id":"2566498997","title":"Lixte Biotechnology Holdings Inc. Files Initial Beneficial Ownership Statement for Director Guy Primus","url":"https://stock-news.laohu8.com/highlight/detail?id=2566498997","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566498997?lang=en_us&edition=fundamental","pubTime":"2025-09-11 02:20","pubTimestamp":1757528434,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has filed an initial statement of beneficial ownership. The filing names Guy Warren Primus as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL4vy6G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1683},{"period":"3month","weight":-0.2422},{"period":"6month","weight":-0.1601},{"period":"1year","weight":0.3918},{"period":"ytd","weight":-0.1323}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.143914},{"month":2,"riseRate":0.714286,"avgChangeRate":0.106103},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.047366},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.105051},{"month":5,"riseRate":0.375,"avgChangeRate":-0.005082},{"month":6,"riseRate":0.5,"avgChangeRate":0.031165},{"month":7,"riseRate":0.625,"avgChangeRate":0.400968},{"month":8,"riseRate":0.5,"avgChangeRate":0.097631},{"month":9,"riseRate":0.375,"avgChangeRate":0.00973},{"month":10,"riseRate":0.375,"avgChangeRate":-0.019298},{"month":11,"riseRate":0.375,"avgChangeRate":-0.035386},{"month":12,"riseRate":0.25,"avgChangeRate":-0.145393}],"exchange":"NASDAQ","name":"Lixte Biotechnology Holdings Inc.","nameEN":"Lixte Biotechnology Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lixte Biotechnology Holdings Inc.,LIXT,Lixte Biotechnology Holdings Inc.股票,Lixte Biotechnology Holdings Inc.股票老虎,Lixte Biotechnology Holdings Inc.股票老虎国际,Lixte Biotechnology Holdings Inc.行情,Lixte Biotechnology Holdings Inc.股票行情,Lixte Biotechnology Holdings Inc.股价,Lixte Biotechnology Holdings Inc.股市,Lixte Biotechnology Holdings Inc.股票价格,Lixte Biotechnology Holdings Inc.股票交易,Lixte Biotechnology Holdings Inc.股票购买,Lixte Biotechnology Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}